skip to main content

Benign prostatic enlargement with tamsulosin exposure before cataract surgery — MSRA MCQ

Instant feedback + full explanation. One question, done properly.

HardLUTSBenign prostatic enlargement with tamsulosin exposure before cataract surgeryMSRA

A 76-year-old man has bothersome mixed voiding and storage LUTS attributed to benign prostatic enlargement. His symptoms are well controlled with tamsulosin MR 400 micrograms once daily, started 18 months ago. He has no dizziness, syncope or postural symptoms. He is due to undergo elective cataract surgery in 5 weeks and asks whether he should stop tamsulosin beforehand. The pre-operative ophthalmology questionnaire does not mention his tamsulosin use. What is the most appropriate management plan?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Continue tamsulosin and ensure that the ophthalmic surgical team is informed of current and previous exposure

Explanation lettering: E = shown as A · A = shown as C · C = shown as E

Tamsulosin is associated with intraoperative floppy iris syndrome (IFIS) during cataract surgery, which can increase peri-operative ophthalmic complications. The key action is therefore to ensure that the ophthalmic team knows that he is currently taking, and has previously taken, tamsulosin so that appropriate intraoperative measures can be planned. Stopping tamsulosin 1–2 weeks before surgery has been suggested historically, but the SmPC states that benefit from discontinuation has not been established; IFIS has also occurred after treatment was stopped for longer periods. In a man whose LUTS are satisfactorily controlled and who has no drug-related adverse effects, routine cessation risks symptom recurrence without reliably removing the surgical risk. A is therefore not the best plan. C is inappropriate because changing alpha-blocker does not address the relevant documented exposure and may destabilise symptom control. D is unsuitable: finasteride has a delayed benefit, is not an equivalent short-term substitute, and should not be started solely to avoid a peri-operative tamsulosin issue. E is disproportionate because cataract surgery can proceed when the surgical team is appropriately alerted.

Reference: Tamsulosin hydrochloride SUN Pharma 400 micrograms prolonged-release hard capsules – Summary of Product Characteristics (Revised 9 April 2025) — https://www.medicines.org.uk/emc/product/2508/smpc Tamsulosin hydrochloride SUN Pharma 400 micrograms prolonged-release hard capsules – Summary of Product Characteristics (Revised 9 April 2025) — https://www.medicines.org.uk/emc/product/2508/smpc